Researchers at UC Davis Comprehensive Cancer Center have unveiled a new gene therapy that targets a type of cancer linked to a herpes virus. This innovative approach aims to treat Kaposi’s sarcoma, a significant health concern for people living with HIV/AIDS, especially in regions like sub-Saharan Africa.
The study, led by Professor Yoshihiro Izumiya, highlights a method that selectively attacks cancer cells infected with the Kaposi’s sarcoma-associated herpesvirus (KSHV) while sparing healthy cells. “This strategy uses a targeted gene therapy technique to focus on virus-infected cells,” Izumiya noted. Research conducted using mouse models showed a marked reduction in tumor growth without any side effects.
The therapy employs a harmless virus, known as the adeno-associated virus (AAV), as a delivery system. It sends a genetic “Trojan horse” into cancer cells. This method specifically activates in KSHV-infected cells thanks to a protein called LANA, found only in those cells. Once inside, the therapy introduces a modified enzyme that transforms the anti-herpes drug ganciclovir into a cancer-fighting agent. As a result, only the infected cells are affected.
During testing, this approach showed success in destroying KSHV-infected cells and halting tumor growth in lab-grown human cells and in mice. Remarkably, there were no adverse side effects observed in these tests, emphasizing the potential safety of this treatment. Furthermore, researchers found that certain anti-cancer drugs could amplify the effectiveness of this gene therapy.
KSHV is linked to aggressive cancers like Kaposi’s sarcoma and some lymphomas. Current treatment options are not only sometimes ineffective but can also lead to severe side effects, particularly for immunocompromised individuals. This new therapy may pave the way for safer, more effective treatments that minimize harm to healthy tissues.
While this research is still in its early stages, it opens up exciting prospects for future cancer treatments. As Izumiya puts it, “Our aim is to exploit the virus’s weaknesses.” If successful, this could mark a significant leap towards personalized cancer therapies.
The study was supported by the National Cancer Institute and the American Cancer Society. You can read more detailed findings in the December issue of Molecular Therapy Oncology.
Advancements like these are crucial. As cancer treatments evolve, understanding how to use existing viruses in therapies has become a trending topic in medical research. Success in this field could lead to more targeted, effective options for patients worldwide.
